[Ip-health] Gilead press release on tenfovir in India

[Mike Palmedo]

http://www.gilead.com/wt/sec/pr_1147371459

Gilead Offers Voluntary Licenses for Manufacturing of Viread in
Developing World

May 10, 2006

Gilead is offering non-exclusive, voluntary licenses to generic
manufacturers in India for the local Indian market as well as provision
for manufacturers to export product to the 97 developing world countries
included in Gilead=92s access program. We are in discussions with a number
of interested parties and welcome requests from others. We will provide
more details as these agreements are finalized. We believe that multiple
manufacturers will ensure competitive prices and the broadest access
possible in these least developed countries.

Gilead filed a patent application for Viread=AE (tenofovir disoproxil
fumarate) in India, and we expect this patent to issue shortly. We
disagree with statements that Viread should not be patented; we believe
that Viread represents innovation and is patentable under Indian law. We
will use this patent responsibly, and will not block access to our
medication in India or in other resource-limited countries where the HIV
epidemic has hit the hardest.

We remain committed to completing registrational filings in all
countries of the company=92s access program. Applications in 61 countries
have been completed, and the remaining filings will be submitted before
year end.